Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 74Breast Neoplasms 53Colorectal Neoplasms 48Neoplasms 39Multiple Myeloma 33Advanced Solid Tumors 33Prostatic Neoplasms 30Ovarian Neoplasms 28Carcinoma, Hepatocellular 28Recurrence 27Neoplasm Metastasis 27Lung Neoplasms 27Pancreatic Neoplasms 26Advanced Solid Tumor 22Small Cell Lung Carcinoma 19Leukemia, Myeloid, Acute 19Endometrial Neoplasms 19Melanoma 18Triple Negative Breast Neoplasms 15Stomach Neoplasms 14Lymphoma, Follicular 14Lymphoma, B-Cell 13Glioma 13Glioblastoma 13Squamous Cell Carcinoma of Head and Neck 12Uterine Cervical Neoplasms 11Lymphoma 11Solid Tumor 10Head and Neck Neoplasms 10Esophageal Neoplasms 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × Neurofibromatosis 2 × Clear all
NCT07131722 2026-01-23

Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II

PRG Science & Technology Co., Ltd.

Phase 1/2 Not yet recruiting
25 enrolled
CNS

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡